U of M startup Miromatrix Medical Inc. has received funding to further develop and test its technology to grow organs from cells.
The company strips cells from pig organs, leaving behind a collagen scaffold. Miromatrix then “recellularizes” that scaffold with cells taken from a patient. The goal is to quickly create organs compatible with a patient’s body so people don’t have to wait for a donor organ to become available.
Miromatrix is now developing transplantable livers and kidneys. The company doesn’t expect to begin testing the organs in humans until the end of 2020, Ross said. However, it does already have two products on the market: Miroderm, which is used for managing wounds, and Miromesh, a product that reinforces soft tissue and is used during plastic and reconstructive surgery.
Read the full story Minneapolis/St. Paul Business Journal.